Support our Foundation of Myology project
Efgartigimod is more rapidly effective than intravenous immunoglobulins in myasthenia gravis
Partager sur
Chinese clinicians compared two immunotherapies for generalised forms of autoimmune myasthenia gravis:
- 51 patients with moderate to severe myasthenia gravis requiring immunotherapy took part in the study,
- 26 received a single course of intravenous efgartigimod, whilst the other 25 received intravenous immunoglobulins,
- after one month of treatment, the efgartigimod group reached a minimal level of symptoms more quickly than the immunoglobulin group,
- this benefit was also greater in terms of daily activity scores (MGADL),
- however, this advantage diminished over time, after three and six months of treatment.
To achieve a faster therapeutic response, the authors recommend the use of efgartigimod.
